Abstract
Astra announced the initiation of its MERIT-HF*trial at the 18th Congress of the European Society of Cardiology (ESC) [Birmingham, UK; August 1996]. The 3000-patient trial will assess the role of the β-blocker metoprolol in the treatment of heart failure. Metoprolol will be given to patients in addition to their existing heart failure regimens. In another development, a study is being planned to investigate the effects of the angiotensin II antagonist candesartan cilexetil in elderly patients with mild hypertension. It is hoped that the agent will improve survival and reduce the risk of vascular dementia in this patient population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
